The standard treatment of LBC A/B includes endocrine therapy targeting ER to inhibit tumor growth, with selective estrogen receptor modulators (tamoxifen), aromatase inhibitors (letrozole and anastrozole), and selective estrogen receptor degraders (fulvestrant and elacestrant). The gene discussed is ESR1; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.